Japan, U.S. Said To Plan Review Standards For iPS-Based Treatments
This article was originally published in PharmAsia News
Executive Summary
Japan and the U.S. have agreed to unify the standards each follows in reviewing regenerative medicines that are based on induced pluripotent stem cells, according to sources.